Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Beckmann

Showing results (801-810 of 1,041) with videos related to

Pageof 105
Sort By:
Breast (Edinburgh, Scotland)|November 4, 2017
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registryAndreas D Hartkopf, Jens Huober, Bernhard Volz, et al.
Cancers|July 20, 2021
Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment SurveillanceHeike Hoyer, Grit Mehlhorn, Cornelia Scheungraber, et al.
Geburtshilfe Und Frauenheilkunde|February 23, 2019
Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) - Part 2 on Triage, Treatment and Follow-upPeter Hillemanns, Klaus Friese, Christian Dannecker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2022
Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast CancerPeter A Fasching, Duan Liu, Steve Scully, et al.
Geburtshilfe Und Frauenheilkunde|October 3, 2022
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANTTobias Engler, Peter A Fasching, Diana Lüftner, et al.
International Journal of Cancer|June 24, 2015
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto studyAlexander Hein, Diether Lambrechts, Gunter von Minckwitz, et al.
Geburtshilfe Und Frauenheilkunde|February 23, 2019
Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) - Part 1 with Introduction, Screening and the Pathology of Cervical DysplasiaPeter Hillemanns, Klaus Friese, Christian Dannecker, et al.
Breast (Edinburgh, Scotland)|September 21, 2020
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in GermanyAndreas Schneeweiss, Johannes Ettl, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|February 14, 2025
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancerChristina B Walter, Andreas D Hartkopf, Alexander Hein, et al.
Cancers|October 27, 2022
Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA ConsortiumFlorian Lüke, Florian Haller, Kirsten Utpatel, et al.
Pageof 105

Showing results (801-810 of 1,041) with videos related to

Sort By:
Pageof 105
Breast (Edinburgh, Scotland)|November 4, 2017
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registryAndreas D Hartkopf, Jens Huober, Bernhard Volz, et al.
Cancers|July 20, 2021
Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment SurveillanceHeike Hoyer, Grit Mehlhorn, Cornelia Scheungraber, et al.
Geburtshilfe Und Frauenheilkunde|February 23, 2019
Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) - Part 2 on Triage, Treatment and Follow-upPeter Hillemanns, Klaus Friese, Christian Dannecker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2022
Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast CancerPeter A Fasching, Duan Liu, Steve Scully, et al.
Geburtshilfe Und Frauenheilkunde|October 3, 2022
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANTTobias Engler, Peter A Fasching, Diana Lüftner, et al.
International Journal of Cancer|June 24, 2015
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto studyAlexander Hein, Diether Lambrechts, Gunter von Minckwitz, et al.
Geburtshilfe Und Frauenheilkunde|February 23, 2019
Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) - Part 1 with Introduction, Screening and the Pathology of Cervical DysplasiaPeter Hillemanns, Klaus Friese, Christian Dannecker, et al.
Breast (Edinburgh, Scotland)|September 21, 2020
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in GermanyAndreas Schneeweiss, Johannes Ettl, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|February 14, 2025
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancerChristina B Walter, Andreas D Hartkopf, Alexander Hein, et al.
Cancers|October 27, 2022
Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA ConsortiumFlorian Lüke, Florian Haller, Kirsten Utpatel, et al.
Pageof 105